Podcasts about Chemotherapy

In this eye-opening conversation, Dr. Vaughn Lawrence (Spirit of Health KC) joins This Is Kansas City to break down a very different way of understanding cancer, tumors, and chronic disease.We talk about:-Why cancer rates have exploded over the last 100 years-How toxicity, chemicals, pesticides, and processed foods overload the body-What tumors may actually represent in the body's “take out the trash” system-The role of sugar, acidity, and oxygen in feeding or starving cancer cells-Why detoxification and organ cleanses (liver, kidneys, colon, lymph) matter-Where chemo, radiation, and pharmaceuticals fit into the bigger picturePractical first steps: clean diet, hydration, cleansing, and targeted labsWhether you're currently dealing with cancer, supporting a loved one, or simply want to prevent disease and live cleaner in a toxic world, this episode will challenge how you think about health — and point you back to God's design for the human body.To find out how we can help you on your health journey, book a free 15-minute Discovery Call with one of our New Client Coordinators! Click the link: https://www.spiritofhealthkc.com/discoverycallFor more health tips and information visit: https://www.spiritofhealthkc.com/To buy natural health supplements visit: http://store.spiritofhealthkc.comFacebook: https://www.facebook.com/SpiritofHealth/Instagram: https://www.instagram.com/spiritofhealthkc/Pinterest: https://www.pinterest.com/spiritofhealthkc/YouTube: https://www.youtube.com/channel/UCwRcNSxR3kMYi9wP8OmxlQQSpotify: https://open.spotify.com/show/7yfBBUjWKk3yJ3auK71O7H?si=295c77ed21f14568&nd=1&dlsi=af01c00121ed4aed

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInHumanity Rx PodcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gugs Mhlungu speaks to Nedine Moonsamy, head of English at the University of Johannesburg, and an award-winning writer, about her new poetry collection, Oh Yes, I Can-cer, and its exploration of cancer, women’s health, diagnosis, treatment, pain and the complexities of finding humour and meaning through illness. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

Welcome to The Daily Wrap Up, an in-depth investigatory show dedicated to bringing you the most relevant independent news, as we see it, from the last 24 hours (9/23/26). As always, take the information discussed in the video below and research it for yourself, and come to your own conclusions. Anyone telling you what the truth is, or claiming they have the answer, is likely leading you astray, for one reason or another. Stay Vigilant. !function(r,u,m,b,l,e){r._Rumble=b,r[b]||(r[b]=function(){(r[b]._=r[b]._||[]).push(arguments);if(r[b]._.length==1){l=u.createElement(m),e=u.getElementsByTagName(m)[0],l.async=1,l.src="https://rumble.com/embedJS/u2q643"+(arguments[1].video?'.'+arguments[1].video:'')+"/?url="+encodeURIComponent(location.href)+"&args="+encodeURIComponent(JSON.stringify([].slice.apply(arguments))),e.parentNode.insertBefore(l,e)}})}(window, document, "script", "Rumble");   Rumble("play", {"video":"v7dq8q2","div":"rumble_v7dq8q2"}); Source Links (In Chronological Order): (14) Megatron on X: "

Send Zorba a message!Zorba looks at new research about how one's diet affects men's sperm count. He helps a caller who has questions about using a cooling treatment to help preserve her air during chemotherapy. Zorba talks about his father's entrepreneurial endeavor developing and selling the "Yuppy Puppy" -- a gumball machine for dogs. He answers emails about eating nuts to help control cholesterol, and new prescription eye drops to help with near-sightedness.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba looks at new research about how one's diet affects men's sperm count. He helps a caller who has questions about using a cooling treatment to help preserve her air during chemotherapy. Zorba talks about his father's entrepreneurial endeavor developing and selling the "Yuppy Puppy" -- a gumball machine for dogs. He answers emails about eating nuts to help control cholesterol, and new prescription eye drops to help with near-sightedness.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Fitz Koehler is a fitness expert, race announcer, author, and breast cancer survivor whose career spans decades of helping people move, train, and live healthier lives. After earning a master's degree in exercise and sport sciences, she built the Fitzness brand, launched the Morning Mile school fitness program, and became one of the country's most recognizable voices at endurance events before cancer abruptly shifted the conversation. She spent 15 months enduring chemotherapy, surgery, and radiation after discovering breast cancer shortly after receiving a clean mammogram. She kept traveling, announcing races, and working through treatment while watching the body she had spent a lifetime building become weaker by the week. Instead of asking why cancer happened, she focused on the only things she believed remained under her control: movement, nutrition, sleep, and mental health. The conversation explores where personal agency ends and biology takes over. Koehler argues that exercise is not about chasing perfection or preventing every diagnosis. It is about building physical reserve before illness arrives and preserving strength, mobility, and independence during treatment. She rejects wellness snake oil, fad supplements, and miracle cures in favor of practical habits rooted in exercise science and lived experience. The discussion also confronts a harder truth. Koehler did everything “right” and still developed cancer. That tension becomes the center of the episode. Fitness cannot eliminate randomness, but it can influence how people experience treatment, recover from surgery, and reclaim their lives afterward. The conversation moves beyond motivation and into survivorship, exercise oncology, cancer rehabilitation, evidence-based nutrition, and the limits of individual control inside a healthcare system that often tells patients what they should do without showing them how to do it. Along the way, the conversation wanders through kickboxing, Cinnabon, Jean-Claude Van Damme, chocolate-covered Cheetos, Jerry Seinfeld playing during chemotherapy stretches, and why the simplest advice is often the hardest to follow. Beneath the humor sits a larger argument: preparing the body for hardship is not about living forever. It is about living better when life inevitably gets difficult. RELATED LINKSFitz Koehler⁠Fitzness⁠The Morning Mile⁠You. Supercharged!⁠My Noisy Cancer Comeback⁠Your Healthy Cancer Comeback⁠UF Health Cancer Center⁠American College of Sports Medicine Exercise Is Medicine⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

https://mayfairsilk.com/blogs/general/silk-pillowcases-for-chemo-patients-benefits-where-to-buyUp to 65% of chemo patients face hair loss, but the scalp pain that comes with it often goes overlooked. Could something as simple as your pillowcase fabric be making trichodynia worse or better? Mayfairsilk City: London Address: 13 Hanover Square Website: https://www.mayfairsilk.com

"Unlike our cancer indications where we use these medications often to activate the immune system to target cancerous cells, in noncancer indications, the goal is really to either suppress an overactive immune or inflammatory cells or modulate the immune system. Immune modulation by use of chemotherapy and immunotherapy can help reduce abnormal inflammation, decrease autoantibody production, and also can alter T-cell and B-cell activity," ONS member Kelsey Miller, MSN, RN, AGCNS-BC, OCN®, clinical nurse specialist in oncology and infusion therapy at Reading Hospital in West Reading, PA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about chemotherapy and immunotherapy for noncancer indications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 18, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the use of anticancer therapies for noncancer indications. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 152: Administer Rituximab Immunotherapy With Confidence ONS Voice articles: JAK1 Inhibitor Quickly Relieves ICI-Related Dermatitis Oncology Drug Reference Sheet: Cyclophosphamide Oncology Drug Reference Sheet: Methotrexate What Oncology Nurses Need to Know About Arboviral Disease in Patients Receiving B-Cell–Depleting or –Modulating Therapies ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Clinical Journal of Oncology Nursing article: Early Recognition and Response of Chemotherapy-Induced Hypersensitivity Reactions: A Nursing Discussion ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Safe Handling Basics Vascular Access Devices ONS Huddle Cards: Anaphylaxis Monoclonal Antibodies ONS position statement: Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies American Academy of Neurology: Practice Guideline Recommendations: Disease-Modifying Therapies for Adults With Multiple Sclerosis American College of Rheumatology: Treatments National Multiple Sclerosis Society: Infused therapies Injectable therapies Medications Used Off-Label NCODA Patient Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The most common immunotherapy agent that's well known to both oncology and other autoimmune disorders is rituximab. And that is used for rheumatoid arthritis, granulomatous, and antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. And then it also has many off-label indications for other autoimmune disorders, such as lupus and multiple sclerosis. It's also used in immune thrombocytopenia and Sjogren's condition." TS 3:28 "Two common chemotherapy agents that come to mind that are used in lower doses for noncancer conditions are methotrexate, which helps modify the underlying disease process to reduce inflammation and preserve organ and joint function. And that's most commonly used rheumatology-wise first-line for rheumatoid arthritis and psoriatic arthritis. A second chemotherapy agent that's well known to oncology is cyclophosphamide, and that really serves as a powerful immunosuppressant for conditions such as ANCA-associated vasculitis and severe lupus nephritis." TS 3:57 "When talking about the monoclonal antibody frequency, it's often shorter in our oncology indications. We may see it weekly, every 21 days, every 28 days—compared to our autoimmune disorders that are months in between. This is really due to cancer cells continuously proliferating, so we need to stop the growth and not allow residual cancer cells to remain. And for the monoclonal antibodies, for example, rituximab again, it's depleting B cells that contribute to autoantibody production and inflammation. So targeting that after one to two infusions, the peripheral B cells are often depleted within days to weeks because of how well the drug works, how targeted it is. Those effects may persist for 6–12 months or even longer." TS 8:39 "Infection prevention education—it's so important to get to know the patient to individualize your teaching. For example, you need to know what matters most of the patients when they go home. Are they taking care of their grandchildren? Do they love to go outside and garden and do mulching? Are they cleaning up their chicken coop? So those kind of things, as a nurse, you can then help tailor your education so you can help prevent infection in these patients because I don't think just standard run-of-the-mill infection prevention teaching is as beneficial as when you can individualize it for that patient." TS 17:33 "If organizations are going to allow non-oncology nurses to administer, we just want to make sure that there is an established process or a protocol to administer rescue medications. That may include what you're already doing if you have a change in patient condition—calling for activating that emergency response system if you're in an inpatient setting. When we look at our ambulatory infusion centers that may have non-oncology nurses administering, you still have to have that training and competency verification and also emergency medical equipment readily available. That would include oxygen and your rescue medications. For the non-oncology nurse, some key points are to make sure that you check on your patient throughout these infusions and have that conversation up front to report any symptoms, both big and small." TS 23:06 "For safe handling, there are many misconceptions that it differs between cancer and non-cancer. When I first started at our organization, even some providers may minimize the risk for low-dose oral chemotherapy. However, it's still metabolized and excreted through our bodily fluids. And we know that traditional chemotherapy, like methotrexate and cyclophosphamide, is cytotoxic. So if a patient's prescribed them for noncancer indications, you still need to cover the basics, like shared bathrooms, what to do if there's contaminated linen, and also bring up the topic of contraception to ensure that our patients and their partners remain safe and do not get exposed." TS 27:13

Seamstresses across Ohio are providing zippered shirts to cancer patients so they can more comfortably undergo chemotherapy treatments.

See omnystudio.com/listener for privacy information.

Guest: Jonathon B. Cohen, MD, MS As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He's a board-certified hematologist and medical oncologist at Emory Winship Cancer Institute in Atlanta, and he spoke about this topic at the 2026 Society of Hematologic Oncology Annual Meeting.

Guest: Jonathon B. Cohen, MD, MS As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He's a board-certified hematologist and medical oncologist at Emory Winship Cancer Institute in Atlanta, and he spoke about this topic at the 2026 Society of Hematologic Oncology Annual Meeting.

Jeremy Heffner, MD, FACS is a board-certified trauma surgeon, former Chair of Surgery at Lima Memorial Health System, and cofounder of Surgery Unified, one of the largest physician-led communities in surgery. His perspective carries weight because he has spent decades inside operating rooms, hospital leadership, physician culture, and the growing collision between medicine and corporate healthcare. He grew up in a blue-collar Ohio family of firefighters, railroad workers, police officers, and tradespeople. Medicine represented something rare: a career that combined service, stability, and purpose. He pursued engineering, earned his medical degree, completed trauma surgery fellowship training at the University of Michigan, and entered a profession that taught physicians to sacrifice themselves for patients.Then the rules changed.This conversation traces the gap between the medicine physicians were trained to practice and the healthcare industry that emerged around them. Administrative burden expanded. Insurance companies gained influence over treatment decisions. Prior authorization became routine. Hospital systems consolidated. Physicians retained responsibility for outcomes while losing authority over the conditions required to achieve them.Heffner describes watching colleagues struggle with burnout, moral injury, PTSD, and growing frustration with a system that increasingly inserts business incentives between clinicians and patients. He explains why younger physicians are entering medicine with a level of visibility that previous generations never had. They see the paperwork, the denials, the loss of autonomy, and the personal cost before they ever finish training.The discussion moves beyond physician dissatisfaction and into the broader consequences for patients. When insurers delay care, hospitals absorb costs, clinicians absorb stress, and patients absorb uncertainty. The financial incentives remain intact while trust erodes across every level of the healthcare system.At its core, this episode examines what happens when a profession built around service finds itself operating inside an industry built around extraction. The result affects physicians, nurses, caregivers, and every patient forced to navigate the consequences.RELATED LINKSJeremy Heffner⁠Surgery Unified⁠SurgeOn⁠University of Michigan Department of Surgery⁠KevinMD⁠Suck It Up Buttercup⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1971, the National Cancer Act transformed cancer into a national research priority. More than 50 years later, the next frontier is no longer defined solely by scientific discovery, but by how quickly knowledge, lived experience, and patient voices can reshape healthcare itself.The concluding chapter of The Cancer Mavericks: A History of Survivorship explores how the cancer advocacy movement continues to evolve in an era of digital communities, social media, precision medicine, and grassroots activism. Building on the work of pioneers such as Mary Lasker, Rose Kushner, and the generations of survivors who followed, today's advocates are expanding the movement beyond awareness to demand health equity, trusted information, patient-centered research, and meaningful representation in healthcare decision-making.The episode examines how technology has transformed advocacy from local support groups into global communities capable of organizing in real time. Researchers, policymakers, nonprofit leaders, and survivors reflect on the growing influence of digital storytelling, online education, and peer-to-peer networks that connect patients across diagnoses, generations, and geographic boundaries. At the same time, they acknowledge new responsibilities: ensuring accurate medical information, combating misinformation, protecting trust, and keeping patients at the center of innovation.The story also looks ahead to the next generation of advocates. Young leaders are applying lessons learned from decades of cancer activism while drawing inspiration from broader movements for social justice, public health, and community organizing. Their work reflects a simple but enduring truth: meaningful change rarely begins inside institutions. It begins when ordinary people refuse to accept that the system cannot improve.Cancer survivorship has never been a finished story. Every generation inherits the progress achieved by those who came before while confronting challenges uniquely its own. The future of survivorship will be shaped not only by scientific breakthroughs, but by those willing to listen, organize, educate, and ensure that every patient's voice helps define what comes next.RELATED LINKSNational Cancer Institute⁠Cancer Moonshot⁠Centers for Disease Control and Prevention | Division of Cancer Prevention and Control⁠HopeLab⁠Tigerlily Foundation⁠Stupid Cancer⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

We meet Mitch McPherson, a Georgia law enforcement officer who was diagnosed with high risk myelofibrosis in February 2025. His symptoms began months earlier with fatigue, weakness, shortness of breath, and facial tingling. Mitch learned that a stem cell transplant offered his best path forward, but his doctors worried that finding a young, fully matched donor could be difficult. Within days, Mitch received unexpected news. Multiple donors were perfect 10 out of 10 matches. The first donor could not meet the required schedule, but a second donor, a 26 year-old woman from the United States, agreed to proceed. Mitch also received support from DKMS and members of his sheriff's department, who organized a donor registration drive. Before the transplant, Mitch took Vonjo to reduce the risk of his disease progressing to leukemia. He then completed five days of intensive chemotherapy and received his stem cell transplant on June 11, 2025. Due to his fitness. he tolerated intense chemotherapy better than he expected, but the effects became more difficult during the following weeks. At one point, he took about 27 pills twice a day. Mitch later developed Graft Versus Host Disease, or GvHD. It caused mouth pain, dry eyes, itching, fatigue, weakness, altered taste, and difficulty eating. Foods with vinegar burned his mouth, while soft foods, dairy, fruit, baked potatoes, and bean burritos were easier to tolerate. The illness also reduced his strength so severely that he had to begin rebuilding muscle with five pound dumbbells. His recovery became harder because he returned to work far earlier than his doctors recommended. He later developed pneumonia and a blood clot in his lung. His doctors then removed him from work for six months. Mitch says the experience changed his outlook and revealed which relationships were dependable. Faith remained central throughout his journey. Interestingly, a year before his diagnosis, Mitch dreamed that Jesus told him he would become sick, but would be okay. That message gave him confidence during his diagnosis, donor search, transplant, and complications. Mitch's strongest advice is simple. We should not try to prove our toughness by ignoring medical guidance. When doctors tell us to rest and allow the body to heal, we need to listen. Mitch now focuses on recovery while finding new outlets through fishing, a possible YouTube channel, and songwriting. Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ (00:00) Intro (01:33) Symptoms and Myelofibrosis Diagnosis (03:51) Multiple Perfect Donor Matches (05:46) Medication, Chemotherapy, and Transplant Preparation (08:43) Living With GvHD (11:27) Support, Isolation, and Changing Relationships (13:44) The Dream That Gave Mitch Hope (16:52) Returning to Law Enforcement After Transplant (20:22) Recovery, Mental Health, and Ongoing Treatment (23:17) Mitch's Advice for Transplant Patients National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Survivor: Africa winner Ethan Zohn joins Rev. Dr. Robin Swan for a powerful conversation about cancer, cannabis, resilience and finding purpose after a life-changing diagnosis. Ethan's life had already taken him from professional soccer to winning CBS's Survivor: Africa when, at age 35, he was diagnosed with a rare form of Hodgkin lymphoma. What followed was an intense medical journey involving chemotherapy, radiation, clinical trials and two stem cell transplants. In this episode, Ethan shares his personal experience with medical cannabis and how it became part of the way he managed some of the physical and emotional challenges surrounding cancer treatment and recovery, including nausea, pain, sleep difficulties and anxiety. Ethan and Robin also discuss the changing conversation around cannabis in professional sports, the importance of responsible education and advocacy, and why patients need honest information when making decisions about their health. The conversation goes far beyond cancer. Ethan explains how surviving a life-threatening illness reshaped his sense of purpose and strengthened his commitment to helping others. He discusses Grassroot Soccer, the nonprofit organization he co-founded that uses the power of soccer to improve the health and lives of young people around the world, as well as Kicking Back, his High Times series exploring the intersection of soccer, cannabis and community. In this episode: Ethan's journey from professional soccer to winning Survivor: Africa Being diagnosed with Hodgkin lymphoma at age 35 Chemotherapy, radiation, clinical trials and two stem cell transplants Ethan's personal experience using cannabis during cancer treatment and recovery Cannabis for nausea, pain, sleep and anxiety The emotional and psychological challenges of cancer survivorship How attitudes toward cannabis are changing in professional sports Cannabis education, responsible use and patient advocacy Turning personal crisis into purpose The story and mission behind Grassroot Soccer Ethan's Kicking Back series with High Times Soccer, cannabis and community Using lived experience to help others facing serious illness Learn more about Ethan Zohn Ethan Zohn:https://ethanzohn.com Grassroot Soccer:https://grassrootsoccer.org Cannabis Health Radio Visit:https://cannabishealthradio.com If this conversation could help someone you know, please share the episode. Subscribe to Cannabis Health Radio for more conversations with patients, advocates, researchers and others exploring cannabis, health and healing. Connect with Cannabis Health RadioVisit us at CannabisHealthRadio.comExplore products and resources from Swan ApothecaryFollow Cannabis Health Radio on Facebook and InstagramImportant DisclaimerThe views and opinions expressed by guests on Cannabis Health Radio (CHR) are their own and do not necessarily reflect those of CHR, its hosts, producers, affiliates, or sponsors. CHR is not responsible for statements or opinions expressed by its guests.Nothing presented in this episode constitutes medical advice, diagnosis, treatment, or a recommendation regarding what you should do. This content is provided for informational and entertainment purposes only. Always consult a qualified healthcare professional regarding your health, medical conditions, medications, or treatment decisions. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Quantum Scientist Patrick Coles Reveals How Tumors Protect Your Mitochondria From Toxic Overload Cancer might not be the enemy your doctor says it is. What if tumors are actually your body's emergency detox system, built on purpose to protect you from something far more dangerous? Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Host Dave Asprey sits down with Patrick Coles, Ph.D., Chief Scientist at Normal Computing, where he develops novel computing hardware for AI applications. Previously a Staff Scientist at Los Alamos National Lab, Coles led their near-term quantum computing group and made significant contributions to quantum computing theory. He holds a Ph.D. in Chemical Engineering from UC Berkeley and a Master of Philosophy in Biochemistry from Cambridge, and he's currently developing a new theory for cancer and chronic disease, the subject of this conversation. His rare combination of hard physics and deep biochemistry gives him a radically different lens on one of medicine's most misunderstood diseases. Coles lays out his Toxin Sequestration Theory, a framework that reframes cancer tumors not as malignant accidents but as intentional storage vaults the body builds to sequester toxins, heavy metals, seed oils, mold, and excess glucose, away from healthy tissue and mitochondria. He and Dave connect the dots between this theory and chronic disease, biohacking fundamentals, and why chemotherapy itself behaves as a toxin that can backfire. They dig into oxalates, deuterium, linoleic acid, circadian biology, and the detox protocols that support the body's natural ability to shrink these toxic reservoirs. This conversation challenges the mainstream genetic theory of cancer, explores the metabolic theory popularized by Thomas Seyfried, and lands on a radical, functional medicine-aligned framework for anyone serious about longevity, anti-aging, and human performance. Dave and Coles also break down how sleep optimization, fasting, ketosis, and a carnivore approach to nutrition support the body's detox hierarchy, from fat tissue and the liver to moles, cysts, and eventually tumors themselves. This is essential listening for anyone serious about biohacking, functional medicine, mitochondria health, brain optimization, nootropics, and taking full control of their metabolism and longevity. You'll Learn: Why toxins may be the root cause of Alzheimer's, Parkinson's, autism, and most chronic disease How Toxin Sequestration Theory reinterprets tumors as the body's backup detox organs Why chemotherapy ranks among the most tissue-damaging toxins, and what happens when a tumor bursts The role of oxalates, deuterium, heavy metals, and seed oils in cancer cell hoarding Why moles, cysts, lipomas, and nodules may be minor versions of the same detox response How circadian rhythm, sleep, and light exposure affect the body's toxin excretion cycles What spontaneous tumor regression reveals about lowering your toxic burden Why tracking tumor progression matters no matter which treatment path you choose Thank you to our sponsors! - Download Dave's Free Peptide Guide at daveasprey.com/peptide-guide. - ZenBud | Dave's Nervous System Biohack. Visit zenbud.health and use code DAVE15 at checkout for a discount. - Timeline | Visit timeline.com/dave to learn more about Mitopure and get 20% off your first order for a limited time. - Just Thrive | Get a free 90-day supply of Digestive Bitters (a $90 value) when you start a 90-day Just Thrive Probiotic subscription at https://get.justthrivehealth.com/pages/asprey Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: toxin sequestration theory, cancer theory, Patrick Coles, quantum computing scientist, thermodynamic computing, Normal Computing, Los Alamos National Lab, chemotherapy toxicity, oxalates cancer, deuterium toxin, Stephanie Seneff, heavy metal detox, mycotoxins tumors, seed oils cancer, linoleic acid, oleic acid oxidation, lipid peroxidation, glucose toxicity, mitochondria downregulation, genetic theory of cancer, metabolic theory of cancer, Thomas Seyfried, spontaneous tumor regression, backup detox organ, circadian rhythm cancer, mold toxins, forever chemicals, microplastics, bile flow, activated charcoal binders, cholestyramine Resources: • Follow Patrick's Work At: https://www.instagram.com/patrickc_tst/ • Watch Gabby's Podcast At: https://www.youtube.com/@GabbyReece • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15? • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 00:58 – Introducing Patrick Coles 04:08 – Toxin Sequestration Theory 06:26 – Defining a Toxin 14:13 – Cancer as Backup Detox Organ 15:01 – History of the Theory 16:30 – Deuterium and Oxalates 21:31 – Cancer Theories Compared 28:06 – Chemotherapy and Toxic Overload 37:23 – Tiered Toxin Storage System 45:17 – Diet, Light, and Circadian Rhythm 50:39 – Detox Protocols and Binders See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | ⁠From Cancer Patient to Cancer Survivor: Lost in Transition⁠National Cancer Institute Office of Cancer Survivorship⁠American Society of Clinical Oncology | Survivorship Compendium⁠CancerCare⁠HopeWell Cancer Support⁠National Coalition for Cancer Survivorship⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer Survivorship⁠Harold P. Freeman Patient Navigation Institute⁠National Cancer Institute Office of Cancer Survivorship⁠Patient Navigator Outreach and Chronic Disease Prevention Act of 2005⁠American Cancer Society⁠Tuskegee Study Timeline | Centers for Disease Control and Prevention⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda Waltman⁠The Margins Matter | JAMA⁠The Margins Matter | PubMed⁠Life Science Editors Foundation⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer Survivorship⁠National Cancer Institute Office of Cancer Survivorship⁠The New England Journal of Medicine⁠Americans with Disabilities Act (ADA.gov)⁠Library of Congress | Civil Rights History Project⁠White Coat, Clenched Fist by Fitzhugh Mullan⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Chemotherapy leaves lasting side effects that don't end with the final infusion. Simple practices like exercise, nutrition, sleep, and supportive wellness tools can help the body reset and recover after treatment. To learn more, visit https://www.healifeco.com/blogs/news/ionic-foot-bath-after-chemotherapy-safety-benefits-side-effects Healifeco City: Sheridan Address: 1309 Coffeen Avenue Website: https://www.healifeco.com/

In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer Institute⁠National Cancer Act of 1971⁠American Cancer Society⁠Dana-Farber Cancer Institute⁠National Library of Medicine⁠The New England Journal of Medicine⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Cancer treatments have changed dramatically over the past decade, but have our dose-finding strategies kept pace? In this episode, I speak with Dr. Ayon Mukherjee, who leads statistical innovation in early oncology development at Eli Lilly. Together, we explore Project Optimus, the FDA initiative that is changing how we think about dose optimization in oncology. Instead of simply finding the highest dose patients can tolerate, Project Optimus encourages us to identify the dose that provides the best balance between efficacy, safety, pharmacokinetics, pharmacodynamics, and long-term tolerability. Ayon explains why the traditional maximum tolerated dose approach worked well for chemotherapy but often falls short for targeted therapies and immunotherapies. We also discuss how statisticians can help lead this transformation by designing better dose optimization studies and collaborating more effectively with clinicians, pharmacologists, and regulators.

Fatigue with biologics… and with Jake Loose, PA-S! [article]Toxic erythema of chemotherapy [article]Juxta-clavicular beaded lines [article]Managing facial hyperpigmentation [article]Want to expand your dermatology knowledge? Check out Summit Derm here!⁠https://medicine.utah.edu/dermatology/education/cme-opportunities/summit⁠Learn more about the U of U Dermatology ECHO model!https://physicians.utah.edu/echo/dermatology-primarycareWant to donate to the cause? Do so here!Donate to the podcast: ⁠⁠uofuhealth.org/dermasphere⁠⁠Check out our video content on YouTube:⁠⁠www.youtube.com/@dermaspherepodcast⁠⁠and VuMedi!: ⁠⁠www.vumedi.com/channel/dermasphere/⁠⁠The University of Utah's DermatologyECHO: ⁠⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠⁠ Connect with us!- Web: ⁠⁠⁠dermaspherepodcast.com/⁠⁠⁠ - Twitter: @⁠DermaspherePC⁠- Instagram: dermaspherepodcast- Facebook: ⁠⁠www.facebook.com/DermaspherePodcast/⁠⁠- Check out Luke and Michelle's other podcast,SkinCast! ⁠⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)- ⁠⁠⁠www.levelex.com/games/top-derm⁠⁠⁠ (A free dermatology game to learn more dermatology!

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At just 16 years old, Hayden Laufgraven heard the words no teenager expects:"You have leukemia."What followed was hospitalisation, chemotherapy, a bone marrow transplant, remission, relapse, another transplant, months of isolation, and learning how to never give up. In this deeply moving episode of Talking Smack 415, Jamie the Great and I sit down with Hayden to talk about what it's really like to be diagnosed with Acute Myeloid Leukemia (AML) as a teenager, the emotional toll of the diagnosis and surviving cancer, and the often-overlooked reality of PTSD after cancer treatment.Hayden shares his remarkable perspective on resilience, friendship, identity, and why surviving cancer doesn't mean the journey is over.Whether you've experienced cancer yourself, love someone who has, or simply need a reminder of the strength of the human spirit, this conversation will stay with you long after it ends. Hayden is wise beyond his years. In this episode we discuss:What it's like being diagnosed with Acute Myeloid Leukemia (AML) at age 16The signs and symptoms that led to his leukemia diagnosisChemotherapy, remission, relapse, and undergoing two bone marrow transplantsHow donor registries and bone marrow matching workThe physical and emotional impact of cancer treatmentPTSD and trauma after surviving cancerRebuilding strength after months of chemotherapy and isolationThe importance of friendship, family, and community during illnessMental resilience and finding hope through uncertaintyLife after cancer and returning to college, sports, and everyday lifeHayden's honesty, maturity, and optimism offer an extraordinary reminder that resilience isn't about pretending you're fearless—it's about continuing to move forward anyway.Follow Hayden on TikTok: @haydenlaufIf this episode resonates with you...Please subscribe, rate, and review Talking Smack 415. Sharing this episode may help someone navigating cancer, supporting a loved one through treatment, or healing from the invisible emotional scars that often remain after remission.Cancer changes lives—but so does hope.Share this episode with your friends and family who love to laugh.  Subscribe to Talking Smack 415 and leave us a rating and review so more peeps can find us for laughter and friendship to feed your soul!  

Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In this episode of OncLive On Air, Gerald Soff, MD, sat down with OncLive to discuss findings from the phase 3 RECITE trial (NCT03362177), which evaluated romiplostim for the management of chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers. Soff is a professor of clinical medicine in the Division of Hematology and chief of the Classical Hematology Section at the University of Miami Miller School of Medicine in Florida.During the interview, Soff reviewed the longstanding unmet need for effective CIT management and explained how thrombopoietin receptor agonists, such as romiplostim, may help maintain platelet counts and preserve chemotherapy delivery; highlighted key findings from RECITE; and discussed the concept of relative dose intensity and why maintaining full-dose chemotherapy remains an important goal in GI oncology care. _____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

"When we think of drug interactions, specifically, the National Cancer Institute actually defines this as a change in the way a drug acts in the body when taken with certain other drugs, herbals, or foods or when taken with certain medical conditions. Drug interactions may cause the drug to either be more or less effective or cause effects on the body that are not expected," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about interaction pathways. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD), including 30 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by July 10, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge related to drug interactions in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series ONS Voice articles: Are Your Patients Taking Herbs That May Interact With Their Cancer Drugs? Pharmacogenomics Testing Helps to Ensure That Effective Therapy Is Safe Therapy Use of Herbal Products Carries Risk for Drug Interactions, but Patient–Clinician Knowledge, Communication Remain Low What the Research Says About Drug Interactions and Medical Cannabis ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS Huddle Cards: DPYD Gene and DPD Enzyme Pharmacogenomics ONS Oral Anticancer Medication Toolkit American Journal of Nursing articles: Understanding Pharmacokinetics: Part1: Drug Absorption Understanding Pharmacokinetics: Part 2: Drug Distribution Understanding Pharmacokinetics: Part 3: Drug Metabolism Understanding Pharmacokinetics: Part 4: Drug Elimination Journal of Nuclear Medicine Technology articles: Pharmacology, Part 1: Introduction to Pharmacology and Pharmacodynamics Pharmacology, Part 2: Introduction to Pharmacokinetics ClinPGx To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "One of the most notable food interactions that interacts with many different medications is actually grapefruit or grapefruit juice. This is known to be a very strong CYP3A4 inhibitor. … A lot of medications are metabolized through the CYP3A4 pathway. By inhibiting the effect of these enzymes, that can actually increase and significantly increase the concentrations of these therapies. It's not an interaction that's just limited to grapefruit. I would say grapefruit being in the food interaction is kind of one of the most well-known, but it can also be seen with other foods as well, like pomegranate juice or a very specific type of orange called Seville oranges. And this is really just due to the presence of a substance called furanocoumarins." TS 6:12 "There have been a pretty large number of genes identified that are responsible for coding some of those common enzyme families that I had been discussing, some of those CYP450 enzymes, but other enzymes as well that are important for drug metabolism. Based on the type of gene, there could be some different categories where patients are normal metabolizers, intermediate metabolizers, or poor metabolizers. There are some other categories as well based on the type of gene we're looking at. And that can ultimately impact the way you are able to metabolize drugs." TS 15:56 "Another common [geneotypic variation] that we always think about in oncology is G6PD, where if someone has G6PD deficiency, these patients can be at greater risk of hemolytic anemias when receiving certain types of therapies. Dapsone and rasburicase are just a couple that have been associated with this risk." TS 17:50 "One of the big concerns is always polypharmacy. Our patients truly can be on a lot of medications. In the field that I work in, transplant, patients automatically from their transplant are on many, many different medications that can potentially predispose them to side effects. … But I think when it comes to the many drug interactions that may flag in these situations, we really have to look at the patient as a whole. Like, how long have these patients been on these therapies? Are they having side effects? Have they been on the combination for a very long time now? So I think that not just looking at the drug reference and seeing that there are like 10 different interactions flagged, but really assessing your patient as a whole can be very important—just because real-world practice, of course, is not black and white. It's often very gray, so it's just important to use clinical judgment in those scenarios." TS 26:10

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailFrom breast cancer surgeon to patient ~ dealing with cancer from both sides Liz O'Riordan grew up in a medical family, and always knew she wanted to become a surgeon. She specialised in breast surgery and has a PHD in thyroid cancers and how they develop.As a female in a male dominated field she has faced bullying and sexual harassment and had a very stressful, high pressured job.She has been a surgeon for over 15 years, and has performed thousands of surgeries. She had lots of knowledge on treating cancer, but when she was diagnosed herself at 40, she found dealing with cancer from the patient's perspective very different.We discuss her own journey, and her hair loss, and how she has learned to embrace her new identity. Liz describes how there can often be an element of reinvention after cancer treatment.Connect with Liz:InstagramWebsiteThe complete guide to breast cancer bookPodcastWill it make the boat go faster? - book Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy:FacebookInstagramTwitterClubhouse- @Hair.TherapyHair Therapy WebsiteDonate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert! 

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.